Aditum Bio

Aditum Bio — from the Latin word for “access” — was founded on a simple mission: to give patients access to medicines that may not otherwise be developed. We are a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities that accelerate drug development. Our agile, collaborative model enables rapid company formation, planning, and execution, empowering teams to explore promising science and bring therapies to patients faster. Guided by our core values — Patient Centric, Collaborative, Curious, and Courageous — we focus on advancing clinic-ready therapies that address significant unmet needs. We are patient centric in our purpose, collaborative in our approach, curious in our pursuit of new science, and courageous in taking on high-impact challenges. Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum Bio manages a broad and growing portfolio of clinical-stage companies focused on improving health outcomes across diverse therapeutic areas. For more information, please visit http://aditumbio.com.